A bayesian model for age, period, and cohort effects on mortality trends for lung cancer, in association with gender-specific incidence and case-fatality rates

Journal of Thoracic Oncology

Volumn 4, Issue 2, 2009, Pages 167-171

  Chien, Chun Ru ^a   Chen, Tony Hsiu Hsi ^b  

^a CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Bayes Theorem; Lung Neoplasms; Treatment Utilization; Trends

Indexed keywords

ANTINEOPLASTIC AGENT;

AGED; ARTICLE; BAYES THEOREM; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURGERY; DRUG UTILIZATION; FEMALE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEX DIFFERENCE; TIME; AGE; COHORT ANALYSIS; COMPARATIVE STUDY; EPIDEMIOLOGY; INCIDENCE; LUNG TUMOR; MORTALITY; STATISTICAL MODEL; TAIWAN;

AGE FACTORS; AGED; BAYES THEOREM; COHORT EFFECT; COHORT STUDIES; FEMALE; HUMANS; INCIDENCE; LUNG NEOPLASMS; MALE; MODELS, STATISTICAL; MORTALITY; SEX FACTORS; TAIWAN; TIME FACTORS;

EID: 65649151062     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318194fabc     Document Type: Article

References (24)

1. http://crs.cph.ntu.edu.tw/crs-e/estimate.htm Accessed January 1, 2008.
2. Liaw YP, Huang YC, Lien GW. Patterns of lung cancer mortality in 23 countries: application of the age-period-cohort model. BMC Public Health 2005;5:22.
3. Lee LT, Lee WC, Lin RS, et al. Age-period-cohort analysis of lung cancer mortality in Taiwan, 1966-1990. Anticancer Res 1994;14:673-676.
4. Luh KT, Chang DB. Primary lung cancer in Taiwan. J Formos Med Assoc 1992;91(Suppl 1):S1-S7.
5. Yang SP, Luh KT, Kuo SH, Lin CC. Chronological observation of epidemiological characteristics of lung cancer in Taiwan with etiological consideration-a 30-year consecutive study. Jpn J Clin Oncol 1984;14: 7-19.
6. Eilstein D, Uhry Z, Lim TA, Bloch J. Lung cancer mortality in France Trend analysis and projection between 1975 and 2012, using a Bayesian age-period-cohort model. Lung Cancer 2008;59:282-290.
7. Bray I. Application of Markov chain Monte Carlo methods to projecting cancer incidence and mortality. J R Stat Soc Ser C Appl Stat 2002;51: 151-164.
8. http://www.moi.gov.tw/stat/english/index.asp Accessed May 26, 2007.
9. Potosky AL, Saxman S, Wallace RB, Lynch CF. Population variations in the initial treatment of non-small-cell lung cancer. J Clin Oncol 2004; 22:3261-3268.
10. Brundage MD, Davies D, Mackillop WJ. Prognostic factors in non-small cell lung cancer: a decade of progress. Chest 2002;122:1037-1057.
11. Albert J. Bayesian selection of log-linear models. Can J Stat 1996;24: 327-347. (Pubitemid 126309223)
12. Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med 2004;350:379-392.
13. Spiro SG, Silvestri GA. One hundred years of lung cancer. Am J Respir Crit Care Med 2005;172:523-529.
14. Wu PF, Chiang TA, Wang TN, et al. Birth cohort effect on lung cancer incidence in Taiwanese women 1981-1998. Eur J Cancer 2005;41: 1170-1177.
15. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005;366: 1527-1537.
16. Osmond C, Gardner MJ. Age, period and cohort models applied to cancer mortality rates. Stat Med 1982;1:245-259.
17. Kaneko S, Ishikawa KB, Yoshimi I, et al. Projection of lung cancer mortality in Japan. Cancer Sci 2003;94:919-923.
18. Socinski MA, Morris DE, Masters GA, Lilenbaum R. Chemotherapeutic management of stage IV non-small cell lung cancer. Chest. 2003;123(1 Suppl):226S-243S.
19. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353: 123-132.
20. Sandler AB, Gray R, Brahmer J, et al. Randomized phase II/III Trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): an Eastern Cooperative Oncology Group (ECOG) Trial-E4599. J Clin Oncol 2005;23(Suppl 16):A-LBA4.
21. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004; 350:351-360. (Pubitemid 38101630)
22. Pirker R, Szczesna A, von Pawel J, et al. FLEX: a randomized, multicenter, phase III study of cetuximab in combination with cisplatin/vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2008;26(20 suppl):Abstract 3.
23. Chien CR, Lai MS. Trends in the pattern of care for lung cancer and their correlation with new clinical evidence: experiences in a universityaffiliated medical center. Am J Med Qual 2006;21:408-414.
24. Alberg AJ, Ford JG, Samet JM. Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007; 132(3 Suppl):29S-55S.